BACK
Vivian Xu
Vice President
New York Office | vivian.xu@torreya.com | 212.257.6026
Vivian Xu, a Vice President at Torreya, provides transaction support for companies across different sectors in the healthcare industry.
Before joining Torreya’s team in 2016, Vivian worked as an Investment Analyst for the healthcare investment team at Fosun Group.
Vivian earned a B.A. in international journalism and communication as well as international economics and trade from Beijing Foreign Studies University. She received her M.A. in public administration from Columbia University, with a concentration in finance and energy. Vivian speaks Mandarin and has extensive experience in English-Chinese two-way translation.
Selected Transactions
|
| Sale of intellectual property to |
|
|
Undisclosed
June 2021
|
|
| R&D collaboration agreement with |
|
|
Undisclosed
February 2021
|
|
| Advisor to the Special Committee of the Board of Directors in its merger with |
|
|
$1.5 billion
October 2020
|
|
| License of Vicineum™ in Greater China Region to |
|
|
$12 million upfront
July 2020
|
|
| License of US rights to Posimir® to |
|
|
$293 million
May 2017
|
|
| License of Nefecon in Greater China and Singapore to |
|
|
Up to $121 million
June 2019
|
|
| Divestiture of China right of Sai Bo Song™ (buprenorphine, naloxone) tablet to |
|
|
Up to $122.5 million
February 2019
|
|
| License of Durasert™ in Ophthalmology in the Greater China Region to |
|
|
Up to $11.75 million
November 2018
|
|
|
| Sale of Sevelamer ANDA to |
|
|
Undisclosed
October 2018
|
|
| License of AJT-240 in hemodialysis in China to |
|
|
Up to $24 million
June 2018
|
|
|
| Sale of ANDA portfolio to |
|
|
Undisclosed
January 2018
|
|
|
| Sale of OTC portfolio to |
|
|
Undisclosed
December 2017
|
|
|
| Sale of generics portfolio to |
|
|
$18 million
August 2017
|
|
| Asset sale to |
|
|
Undisclosed
July 2017
|